Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
One-Month DAPT in CABG Patients
NCT05997693 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.
Conditions Studied
Interventions
- DRUG Low-dose aspirin
- DRUG Ticagrelor 90 MG
Study Locations (20)
Other
- Medical University Graz — Graz
- Johannes Kepler University Linz — Linz
- Medical University of Vienna — Vienna
- Beijing Anzhen Hospital — Beijing
- Center China Fuwai Hospital — Beijing
- University Hospital of Düsseldorf — Düsseldorf
- Westdeutsches Herz- und Gefäßzentrum Essen, Universität Duisburg-Essen — Essen
- Klinik für Herz- und Gefäßchirurgie - Universitäts-Herzzentrum Freiburg - Bad Krozingen — Freiburg im Breisgau
- University Hospital Giessen — Giessen
- Jena University Hospital — Jena
- LMU Klinikum Campus Großhadern — München
- Robert-Bosch-Krankenhaus Stuttgart — Stuttgart
- Sahlgrenska University Hospital — Gothenburg
New York
- NewYork-Presbyterian: Queens Hospital — Flushing
- Weill Cornell Medicine — New York
New Jersey
- Englewood Hospital — Englewood
Innsbruck
- Medical University Innsbruck — Innsbruck
Ontario
- University of Ottawa Heart Institute — Ottawa
China
- Ruijin Hospital: Shanghai Jiao Tong University School of Medicine — Shanghai
Jilian
- Jilin Heart Hospital — Changchun
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2024-08-15 |
| Est. Completion | 2031-01 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05997693
The ClinicalTrials.gov registry entry for NCT05997693 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 679 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Chronic Coronary Disease appearing as the primary indexed condition, and to 2 interventions — of which Low-dose aspirin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05997693 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Other, New York, New Jersey. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05997693 about?
NCT05997693 is a clinical study titled "One-Month DAPT in CABG Patients". The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.
What is the current status of trial NCT05997693?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2024-08-15. Estimated completion is 2031-01.
What conditions does trial NCT05997693 study?
This clinical trial studies the following conditions: Chronic Coronary Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05997693?
The interventions under investigation include: Low-dose aspirin (DRUG), Ticagrelor 90 MG (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05997693?
This trial is sponsored by Weill Medical College of Cornell University, which has 679 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05997693 being conducted?
This trial has 20 study locations across New Jersey, New York, Innsbruck, Ontario, China. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.